The Impact of Tyrosine Kinase Inhibitors on Fatherhood in Patients With Chronic Myeloid Leukemia: A Mixed-Method Study

• Published in: Curēus (Palo Alto, CA) Vol. 15; no. 1; p. e33407
• Main Authors: Abu-Tineh, Mohammad, Ali, Elrazi A, Alshurafa, Awni, Nashwan, Abdulqadir J, Albsheer, Khalid, Ahmed, Ashraf, Hailan, Yousef, Rozi, Waail, Aljaloudi, Esraa, Yassin, Mohamed A
• Format: Journal Article
• Language: English
• Published: United States Cureus Inc 05.01.2023; Cureus
• Subjects: Age; Cancer; Children & youth; Expatriates; Fertility; Hematology; Infertility; Inhibitor drugs; Leukemia; Mixed methods research; Oncology; Patients; Pregnancy; Stillbirth; Targeted cancer therapy; Tumors; Vagina; Womens health; Qatar; tyrosine kinase inhibitors; chronic myeloid leukemia; fatherhood; cml; tkis
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.33407

Multiple studies have demonstrated that tyrosine kinase inhibitors (TKIs) exert a significant extent of control over chronic myeloid leukemia (CML), as evidenced by studies such as the population-based Swedish CML registry, which found that patients reaching age 70 had a relative survival rate close to one when compared to the general population. Consequently, new perspectives on the safety of treatments have emerged, particularly in the context of their impact on fatherhood in men. According to the authors, this is the first study to examine the effect of TKIs on fatherhood in CML patients.  Methods: A single-center, mixed-design study (retrospective data review and phone interviews) was conducted with CML male patients in the chronic or accelerated phase, evaluating the effect of imatinib, dasatinib, and nilotinib on their fatherhood, irrespective of whether they were administered as a first, second, or third line of treatment. The study included interviews with 150 patients. Included were 27 patients. The average age was approximately 44.5 years. One hundred percent of the patients were in the chronic phase. The median age at first conception following TKI therapy was 36, and the median duration of TKI therapy was approximately seven years. The total number of offspring was 49; 98% were born at term and had a normal birth weight. No reports of stillbirths, fetal deaths, or congenital malformations were made. All the offspring grew and developed normally. No CML-related cancers were reported in any of the newborns. Around 98% of male CML patients receiving imatinib, dasatinib, or nilotinib did not experience a negative impact on their fatherhood or the health of their children. However, improved education for patients beginning treatment with TKIs addresses the potential psychological worry of having an unfavorable effect on their fertility or offspring, which may increase medication adherence.